SCHEMBL30451572

SCHEMBL30451572

Brc1cnc2cnccc2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 3/20 0.39
PDGFRA P16234 3/20 0.39
DYRK1A Q13627 3/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
CYP2A6 P11509 1/20 0.37
CSNK1D P48730 1/20 0.37
CSNK1E P49674 1/20 0.37
CLK1 P49759 1/20 0.37
MAPK10 P53779 3/20 0.37
MAP4K4 O95819 1/20 0.37
MINK1 Q8N4C8 1/20 0.37
TNIK Q9UKE5 1/20 0.37
HPGDS O60760 1/20 0.36
BIRC5 O15392 1/20 0.36
EGFR P00533 1/20 0.36
CDK9 P50750 2/20 0.35
CCNT1 O60563 1/20 0.35
PIM1 P11309 1/20 0.35
HASPIN Q8TF76 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8880590 1.00 PDGFRB (0.39) PDGFRBPDGFRADYRK1ACYP11B1CYP11B2
SCHEMBL5928331 0.83 DYRK1A (0.41) PDGFRBPDGFRADYRK1ACYP11B1CYP11B2
SCHEMBL30586650 0.75 MAPK10 (0.45) PDGFRBPDGFRADYRK1ACYP2A6CSNK1D
SCHEMBL276230 0.75 DYRK1A (0.56) PDGFRBPDGFRADYRK1ACYP11B1CYP11B2
SCHEMBL30738180 0.75 MAP4K4 (0.44) PDGFRBPDGFRADYRK1ACYP2A6CSNK1D
SCHEMBL25216279 0.75 PDGFRB (0.47) PDGFRBPDGFRADYRK1ACYP2A6CSNK1D
SCHEMBL18583892 0.75 MAPT (0.40) PDGFRBPDGFRADYRK1ACYP2A6CSNK1D
SCHEMBL2007566 0.75 PDGFRB (0.39) PDGFRBPDGFRADYRK1ACYP2A6CSNK1D
SCHEMBL22384535 0.75 PDGFRB (0.39) PDGFRBPDGFRADYRK1ACYP2A6CSNK1D
SCHEMBL276229 0.75 PDGFRB (0.39) PDGFRBPDGFRADYRK1ACYP2A6CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025034858-A1 FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2025-02-13 WO disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PDGFRB 1234/4885PDGFRA 2368/4885DYRK1A 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.